Novel avenues for Clostridium difficile infection drug discovery

Bibliography

• Larson HE, Price AB, Honour P, Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet 1978;1:1063-6
   PubMed Web of Science ®Google Scholar
• Gerding DN. Clostridium difficile 30 years on: what has, or has not, changed and why? Int J Antimicrob Agents 2009;33(S1):52-8
   PubMedGoogle Scholar
• Bartlett JG. Clostridium difficile infection: historic review. Anaerobe 2009;15:227-9
   PubMed Web of Science ®Google Scholar
• Pépin J, Valiquette L, Alary M-E, Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171:466-72
   PubMed Web of Science ®Google Scholar
• Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. CID 2012;55(Suppl 2):S65-70
   PubMed Web of Science ®Google Scholar
• Wiegand PN, Nathwani D, Wilcox MH, Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 2012;81:1-14
   PubMed Web of Science ®Google Scholar
• Bartlett JG. Clostridium difficile: progress and challenges. Ann NY Acad Sci 2010;1213:62-9
   PubMed Web of Science ®Google Scholar
• Cartman ST, Heap JT, Kuehne SA, The emergence of ‘hypervirulence' in Clostridium difficile. Int J Med Microbiol 2010;300:387-95
   PubMed Web of Science ®Google Scholar
• Deneve C, Janoira C, Poilane I, New trends in Clostridium difficile virulence and pathogenesis. Int J Antimicrob Agents 2009;33(S1):S24-8
   PubMedGoogle Scholar
• Goorhuis A, Bakker D, Corver J, Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008;47:1162-70
   PubMed Web of Science ®Google Scholar
• Gerding DN. Disease associated with Clostridium difficile infection. Ann Intern Med 1989;110:255-7
   PubMed Web of Science ®Google Scholar
• Mani N, Dupuy B. Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor. Proc Natl Acad Sci USA 2001;98:5844-9
   PubMed Web of Science ®Google Scholar
• Kelly CP, LaMont JT. Clostridium difficile - more difficult than ever. N Engl J Med 2008;359:1932-40
   PubMed Web of Science ®Google Scholar
• Carter GP, Rood JI, Lyras D. The role of toxin A and toxin B in the virulence of Clostridium difficile. Trends Microbiol 2012;20:21-9
   Google Scholar
• Bartlett JG. New antimicrobial agents for patients with Clostridium difficile infections. Curr Infect Dis Rep 2009;11:21-8
   PubMedGoogle Scholar
• Huang H, Weintraub A, Fang H, Antimicrobial resistance in Clostridium difficile. Int J Antimicrob Agents 2009;34:516-22
   PubMed Web of Science ®Google Scholar
• Venugopal AA, Johnson S. Current state of Clostridium difficile treatment options. Clin Infect Dis 2012;55(Suppl 2):S71-6
   PubMed Web of Science ®Google Scholar
• Lancaster JW, Matthews SJ. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections. Clin Ther 2012;34:1-13
   PubMed Web of Science ®Google Scholar
• McFarland LV. Emerging therapies for Clostridium difficile infections. Exp Opin Emerg Drugs 2011;16:425-39
   PubMed Web of Science ®Google Scholar
• Mascio CTM, Mortin LI, Howland KT, In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for the treatment of Clostridium difficile. Antimicrob Agents Chemother 2012;56:5023-30
   PubMed Web of Science ®Google Scholar
• Citron DM, Tyrrell KL, Merriam V, In Vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species. Antimicrob Agents Chemother 2012;56:1613-15
   PubMed Web of Science ®Google Scholar
• Freeman J, Baines SD, Jabes D, Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother 2005;56:717-25
   PubMed Web of Science ®Google Scholar
• Macfarlane GT, Macfarlane S, Gibson GR. Validation of a three stage compound continuous culture system for investigating the effect of retention time on the ecology and metabolism of bacteria in the human colon. Microbiol Ecol 1998;35:180-7
   Google Scholar
• Jabes D. The antibiotic R&D pipeline: an update. Curr Opin Microbiol 2011;14:564-9
   PubMed Web of Science ®Google Scholar
• Available from: http://www.nanotherapeutics.com/products_pipeline_ramoplanin.php [Last accessed 2 August 2012]
   Google Scholar
• Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clin Infect Dis 2012;54(Suppl 3):S214-19
   PubMedGoogle Scholar
• Chilton CH, Freeman J, Crowther GS, Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model. J Antimicrob Chemother 2012;67:2434-7
   PubMed Web of Science ®Google Scholar
• Van Bambeke F, Carryn S, Seral C, Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob Agents Chemother 2004;48:2853-60
   PubMed Web of Science ®Google Scholar
• Chritchley IA, Green LS, Young CL, Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections. J Antimicrob Chemother 2009;63:954-63
   PubMed Web of Science ®Google Scholar
• Citron DM, Warren YA, Tyrrell KL, Comparative in vitro activity of REP3123 against Clostridium difficile and other anaerobic intestinal bacteria. J Antimicrob Chemother 2009;63:972-6
   PubMed Web of Science ®Google Scholar
• Ochsner UA, Bell SJ, O'Leary AL, Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model. J Antimicrob Chemother 2009;63:964-71
   PubMed Web of Science ®Google Scholar
• Butler MM, LaMarr WA, Foster KA, Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound. Antimicrob Agents Chemother 2007;51:119-27
   PubMed Web of Science ®Google Scholar
• Butler MM, Shinabarger DL, Citron DM, MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile. Antimicrob Agents Chemother 2012;56:4786-92
   PubMed Web of Science ®Google Scholar
• LaMarche MJ, Leeds JA, Amaral A, Discovery of LFF571: An investigational agent for Clostridium difficile infection. J Med Chem 2012;55:2376-87
   PubMed Web of Science ®Google Scholar
• Available from: clinicaltrials.gov [Last access 16 January 2013]
   Google Scholar
• Available from: www.actelion.com [Last accessed 8 January 2013]
   Google Scholar
• Baldoni D, Gutierrez M, Dingemanse J, Cadazolid, a novel quinolonyl-oxazolidinone antibiotic with potent activity against Clostridium difficile: safety, tolerability, and pharmacokinetics in healthy subjects following single and multiple oral doses. Poster (A-1273), Session 162, presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 9 – 12 September 2012; San Francisco
   Google Scholar
• Chopra I. The magainins: antimicrobial peptides with potential for topical application. J Antimicrob Chemother 1993;32:351-3
   PubMed Web of Science ®Google Scholar
• Wiesner J, Vilcinskas A. Antimicrobial peptides: the ancient arm of the human immune system. Virulence 2010;1:440-64
   PubMed Web of Science ®Google Scholar
• Harris F, Dennison SR, Phoenix DA. Anionic antimicrobial peptides from eukaryotic organisms. Curr Protein Pept Sci 2009;10:585-606
   PubMed Web of Science ®Google Scholar
• Anaya-Lopez JL, Lopez-Meza JE, Ochoa-Zarzosa A. Bacterial resistance to cationic antimicrobial peptides. Crit Rev Microbiol 2012; doi:10.3109/1040841X.2012.699025
   PubMed Web of Science ®Google Scholar
• Lloyd DH. Alternatives to conventional antimicrobial drugs: a review of future prospects. Vet Dermatol 2012;23:299-304
   PubMed Web of Science ®Google Scholar
• Hassan M, Kjos M, Nes IF, Natural antimicrobial peptides from bacteria: characteristics and potential applications to fight against antibiotic resistance. J Appl Microbiol 2012;113:723-36
   PubMed Web of Science ®Google Scholar
• Chatterjee C, Paul M, Xie L, Biosynthesis and mode of action of lantibiotics. Chem Rev 2005;105:633-84
   PubMed Web of Science ®Google Scholar
• Cotter PD, Hill C, Ross RP. Bacteriocins: developing innate immunity for food. Nat Rev Microbiol 2005;3:777-88
   PubMed Web of Science ®Google Scholar
• Ross AC, Vederas JC. Fundamental functionality: recent developments in understanding the structure-activity relationships of lantibiotic peptides. J Antibiot 2011;64:27-34
   PubMed Web of Science ®Google Scholar
• Johnson AP. New antibiotics for selective treatment of gastrointestinal infection caused by Clostridium difficile. Expert Opin Ther Patents 2010;20:1389-99
   PubMed Web of Science ®Google Scholar
• Crowther GS, Baines SD, Todhunter SL, Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection. J Antimicrob Chemother 2013;68:168-76
   PubMed Web of Science ®Google Scholar
• Available from: http://www.wellcome.ac.uk/News/2012/News/WTVM056086.htm [Last accessed 11 January 2013]
   Google Scholar
• Hillman JD, Johnson KP, Yaphe BI. Isolation of a Streptococcus mutans strain producing a novel bacteriocin. Infect Immun 1984;44:141-4
   PubMed Web of Science ®Google Scholar
• Ghobrial OG, Derendorf H, Hillman JD. Pharmacodynamic activity of the lantibiotic MU1140. Int J Antimicrob Agents 2009;33:70-4
   PubMed Web of Science ®Google Scholar
• Available from: http://www.oragenics.com/?q=lantibiotics [Last accessed 22 August 2012]
   Google Scholar
• Corr SC, Li Y, Riedel CU, Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. PNAS 2007;104:7617-21
   PubMed Web of Science ®Google Scholar
• Ryan MP, Rea MC, Hill C, An Application in cheddar cheese manufacture for a strain of Lactococcus lactis producing a novel broad-spectrum bacteriocin, lacticin 3147. Appl Environ Microbiol 1996;62:612-19
   PubMed Web of Science ®Google Scholar
• Rea MC, Clayton E, O'Connor PM. Antimicrobial activity of lacticin 3147 against clinical Clostridium difficile strains. J Med Microbiol 2007;56:940-6
   PubMed Web of Science ®Google Scholar
• Rea MC, Dobson A, O'Sullivan O, Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. PNAS 2011;108(Suppl 1):4639-44
   PubMed Web of Science ®Google Scholar
• Rea MC, Sit CS, Clayton E, Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. PNAS 2010;107:9352-7
   PubMed Web of Science ®Google Scholar
• Murphy K, O'Sullivan O, Rea MC, Genome mining for radical SAM protein determinants reveals multiple sactibiotic-like gene clusters. PLoS One 2011;6:e20852
   PubMedGoogle Scholar
• Sofia HJ, Chen G, Hetzler BG, Radical SAM, a novel protein superfamily linking unresolved steps in familiar biosynthetic pathways with radical mechanisms: functional characterization using new analysis and information visualization methods. Nucleic Acids Res 2001;29:1097-106
   PubMed Web of Science ®Google Scholar
• Zucca M, Scutera S, Savoia D. Antimicrobial peptides: new frontiers in the therapy of infections. In: Drug development. A case study based insight into modern strategies. Rundfeldt, InTech; Croatia: 2011. p. 123-62
   Google Scholar
• Ramasundara M, Leach ST, Lemberg DA, Defensins and inflammation: the role of defensins in inflammatory bowel disease. J Gastroent Hepatol 2009;24:202-8
   Web of Science ®Google Scholar
• Dawson MJ, Scott RW. New horizons for host defense peptides and lantibiotics. Curr Opin Pharmacol 2012;12:1-6
   PubMedGoogle Scholar
• Giesemann T, Guttenberg G, Aktories K. Human alpha-defensins inhibit Clostridium difficile toxin B. Gastroenterology 2008;134:2049-58
   PubMed Web of Science ®Google Scholar
• Chen H, Xu Z, Peng L, Recent advances in the research and development of human defensins. Peptides 2006;27:931-40
   PubMed Web of Science ®Google Scholar
• Wencker M, Brantly ML. Cytotoxic concentrations of alpha-defensins in the lungs of individuals with alpha 1-antitrypsin deficiency and moderate to severe lung disease. Cytokine 2005;32:1-6
   PubMed Web of Science ®Google Scholar
• Hwang JS, Lee J, Kim Y-J, Isolation and characterization of a defensin-like peptide (coprisin) from the dung beetle, Copris tripartitus. Int J Pept 2009;2009: doi:pii 136284. 10.1155/2009/136284; Epub 2009 Oct 22
   PubMedGoogle Scholar
• Scott RW, DeGrado WF, Tew GN. De novo designed synthetic mimics of antimicrobial peptides. Curr Opin Biotechnol 2008;19:620-7
   PubMed Web of Science ®Google Scholar
• Kang JK, Hwang JS, Nam HJ, The insect peptide coprisin prevents Clostridium difficile-mediated acute inflammation and mucosal damage through selective antimicrobial activity. J Antimicrob Agents Chemother 2011;55:4850-7
   PubMed Web of Science ®Google Scholar
• McBride SM, Sonenshein AL. Identification of a genetic locus responsible for antimicrobial peptide resistance in Clostridium difficile. Infect Immun 2011;79:167-76
   PubMed Web of Science ®Google Scholar
• Chen AGY, Sudarsan N, Breaker RB. Mechanism for gene control by a natural allosteric group I ribozyme. RNA 2011;17:1967-72
   PubMed Web of Science ®Google Scholar
• Guan L, Disney MD. Recent advances in developing small molecules targeting RNA. ACS Chem Biol 2012;7:73-86
   PubMed Web of Science ®Google Scholar
• Lee ER, Baker JR, Weinberg Z, An allosteric self-splicing ribozyme triggered by a bacterial second messenger. Science 2010;329:845-8
   PubMed Web of Science ®Google Scholar
• Blount KF, Breaker RR. Riboswitches as antibacterial drug targets. Nat Biotechnol 2006;24:1558-64
   PubMed Web of Science ®Google Scholar
• Deigan KE, Ferrè-D'Amarè AR. Riboswitches: discovery of drugs that target bacterial gene-regulatory RNAs. Accounts Chem Res 2011;44:1329-38
   PubMed Web of Science ®Google Scholar
• Ster C, Allard M, Boulanger S, Experimental treatment of Staphylococcus aureus bovine intramammary infection using a guanine riboswitch ligand analog. J Dairy Sci 2013;96:1-9. Available from: http://dx.doi.org/10.3168/jds.2012-5890
   PubMedGoogle Scholar
• Purcell EB, McKee RW, McBride SM, Cyclic diguanylate inversely regulates motility and aggregation in Clostridium difficile. J Bacteriol 2012;194:3307-16
   PubMed Web of Science ®Google Scholar
• Ethapa T, Leuzzi R, Ng YK, Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile. J Bacteriol 2013;195:545-55
   PubMed Web of Science ®Google Scholar
• Sudarsan N, Lee ER, Weinberg Z, Riboswitches in Eubacteria sense the second messenger cyclic di-GMP. Science 2008;321:411-13
   PubMed Web of Science ®Google Scholar
• Bordeleau E, Fortier LC, Malouin F, c-di-GMP turn-over in Clostridium difficile is controlled by a plethora of diguanylate cyclases and phosphodiesterases. PLoS Genet 2011;7:e1002039
   PubMed Web of Science ®Google Scholar
• Aubry A, Hussack G, Chen W, Modulation of toxin production by the flagellar regulon in Clostridium difficile. Infect Immun 2012;80:3521-32
   PubMed Web of Science ®Google Scholar
• Donelli G, Vuotto C, Cardines R, Biofilm-growing intestinal anaerobic bacteria. FEMS Immunol Med Microbiol 2012;65:318-25
   PubMedGoogle Scholar
• Reynolds CB, Emerson JE, de la Riva L, The Clostridium difficile cell wall protein CwpV is antigenically variable between strains, but exhibits conserved aggregation-promoting function. PLoS Pathog 2011;7:1-14
   Google Scholar
• Furukawa K, Gu H, Sudarsan N, Identification of ligand analogues that control c-di-GMP riboswitches. ACS Chem Biol 2012;7:1436-43
   PubMed Web of Science ®Google Scholar
• Martin CA, Hoven AD, Cook AM. Therapeutic frontiers: preventing and treating infectious diseases by inhibiting bacterial quorum sensing. Eur J Clin Microbiol Infect Dis 2008;27:635-42
   PubMed Web of Science ®Google Scholar
• Pereira CS, Thompson JA, Xavier KB. AI-2-mediated signalling in bacteria. FEMS Microbiol Rev 2012; doi: 10.1111/j.1574-6976.2012.00345
   PubMed Web of Science ®Google Scholar
• Carter GP, Purdy D, Williams P, Quorum sensing in Clostridium difficile: analysis of a luxS-type signalling system. J Med Microbiol 2005;54:119-27
   PubMed Web of Science ®Google Scholar
• Lee ASY, Song KP. LuxS/autoinducer-2 quorum sensing molecule regulates treanscriptional virulence gene expression in Clostridium difficile. Biochem Biophys Res Commun 2005;335:659-66
   PubMed Web of Science ®Google Scholar
• Kaufmann GF, Sartorio R, Lee S-H, Revisiting quorum sensing: discovery of additional chemical and biological functions for3-oxo-N-acylhomoserine lactones. PNAS 2005;102:309-14
   PubMed Web of Science ®Google Scholar
• Ueda C, Tateda K, Horikawa M, Anti-Clostridium difficile potential of tetramic acid derivatives from Pseudomonas aeruginosa quorum-sensing autoinducers. Antimicrob Agents Chemother 2010;54:683-8
   PubMed Web of Science ®Google Scholar
• d'Herelle F. Sur un microbe invisible antagoniste des bacillus dysentérique. C R Acad Sci Paris 1917;165:373-5
   Google Scholar
• Brüssow H. What is needed for phage therapy to become a reality in Western medicine? Virology 2012;434:138-42
   PubMed Web of Science ®Google Scholar
• Abedon ST, Kuhl SJ, Blasdel BG, Phage treatment of human infections. Bacteriophage 2011;1:66-85
   PubMedGoogle Scholar
• Available from: http://www.who.int/dg/speeches/2011/WHD_20110407/en/index/html
   Google Scholar
• Bush K, Courvalin P, Dantas G, Tackling antibiotic resistance. Nat Rev Microbiol 2011;9:894-6
   PubMed Web of Science ®Google Scholar
• Sulakvelidze A. Phage therapy: an attractive option for dealing with antibiotic-resistant bacterial infections. Drug Discov Today 2005;10:807-9
   PubMed Web of Science ®Google Scholar
• Merabishvili M, Pirnay JP, Verbeken G, Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 2009;4:e4944
   PubMed Web of Science ®Google Scholar
• Rhoads DD, Wolcott RD, Kuskowski MA, Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 2009;18:237-43
   PubMedGoogle Scholar
• Wright A, Hawkins CH, Anggard EE, A controlled clinical trial of a therapeutical bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 2009;34:349-57
   PubMed Web of Science ®Google Scholar
• Hawkins C, Harper D, Burch D, Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: a before/after clinical trial. Vet Microbiol 2010;146:309-13
   PubMed Web of Science ®Google Scholar
• Sarker SA, McCallin S, Barretto C, Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology 2012. In press Available from: http://dx.doi.org/10.1016/j.virol.2012.09.002
   Google Scholar
• Brüssow H. Pseudomonas biofilms, cystic fibrosis, and phage: a silver lining? MBio 2012;3:e00061-12
   Google Scholar
• Debarbieux L, Leduc D, Maura D, Bacteriophages can treat and prevent P. aeruginosa lung infections. J Infect Dis 2010;201:1096-104
   PubMed Web of Science ®Google Scholar
• Alemayehu D, Casey PG, McAuliffe O, Bacteriophages ϕMR299-2 and ϕNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio 2012;3:e00029-12
   PubMed Web of Science ®Google Scholar
• Saussereau E, Debarbieux L. Bacteriophages in the experimental treatment of Pseudomonas aeruginosa infections in mice. Adv Virus Res 2012;83:123-41
   PubMed Web of Science ®Google Scholar
• Kutateladze M, Adamia R. Phage therapy experience at the Eliava Institute. Med Mal Infect 2008;38:426-30
   PubMed Web of Science ®Google Scholar
• Międzybrodzki R, Borysowski J, Weber-Dąbrowska B, Clinical aspects of phage therapy. Adv Virus Res 2012;83:73-121
   PubMed Web of Science ®Google Scholar
• Chanisvili N. Phage therapy—history from Twort and d'Herelle through Soviet experience to current approaches. Adv Virus Res 2012;83:3-40
   PubMed Web of Science ®Google Scholar
• Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage 2011;1:111-14
   PubMedGoogle Scholar
• Verbeken G, Pirnay JP, De Vos D, Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. Arch Immunol Ther Exp 2012;60:161-72
   PubMed Web of Science ®Google Scholar
• Parracho HMRT, Burrowes BH, Enright MC, The role of regulated clinical trials in the development of bacteriophage therapeutics. J Mol Genet Med 2012;6:279-86
   PubMedGoogle Scholar
• Ramesh V, Fralich JA, Rolfe RD. Prevention of Clostridium difficile -induced ileocecitis with bacteriophage. Anaerobe 1999;5:269-78
   Google Scholar
• Meader E, Mayer MJ, Gasson MJ, Bacteriophage treatment significantly reduces viable Clostridium difficile and prevents toxin production in an in vitro model system. Anaerobe 2010;16:549-54
   PubMed Web of Science ®Google Scholar
• Available from: www.novolytics.co.uk [Last accessed 31 August 2012]
   Google Scholar
• Hagens S, Bläsi U. Genetically modified filamentous phage as bactericidal agents: a pilot study. Lett Appl Microbiol 2003;37:318-23
   PubMed Web of Science ®Google Scholar
• Perry JD, Asir K, Halimi D, Evaluation of a chromogenic culture medium for isolation of Clostridium difficile within 24 hours. J Clin Microbiol 2010;48:3852-8
   PubMed Web of Science ®Google Scholar
• Loessner MJ. Bacteriophage endolysins- current state of research and applications. Curr Opin Microbiol 2005;8:480-7
   PubMed Web of Science ®Google Scholar
• Borysowski J, Weber-Dabrowska B, Górski A. Bacteriophage endolysins as a novel class of antibacterial agents. Exp Biol Med 2006;231:366-77
   PubMed Web of Science ®Google Scholar
• Fischetti VA. Bacteriophage endolysins: a novel anti-infective to control Gram positive pathogens. Int J Med Microbiol 2010;300:357-62
   PubMed Web of Science ®Google Scholar
• Loeffler JM, Nelson D, Fischetti VA. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 2001;294:2170-2
   PubMed Web of Science ®Google Scholar
• Fischetti VA. Bacteriophage lysins as effective antibacterials. Curr Opin Microbiol 2008;11:393-400
   PubMed Web of Science ®Google Scholar
• Mayer MJ, Narbad A, Gasson MJ. Molecular characterization of a Clostridium difficile bacteriophage and its cloned biologically active endolysin. J Bacteriol 2008;190:6734-40
   PubMed Web of Science ®Google Scholar
• Mayer MJ, Garefalaki V, Spoerl R. Structure-based modification of a Clostridium difficile-targeting endolysin affects activity and host range. J Bacteriol 2011;193:5477-86
   PubMed Web of Science ®Google Scholar
• Ciorba MA. A gastroenterologist's guide to probiotics. Clin Gastroenterol Hepatol 2012;9:960-8
   Google Scholar
• Kotzampassi K, Giamarellos-Bourboulis EJ. Probiotics for infectious diseases: more drugs, less dietary supplementation. Int J Antimicrob Agents 2012;40:288-96
   PubMed Web of Science ®Google Scholar
• Snydman DR. The safety of probiotics. Clin Infect Dis 2008;46(Suppl 2):S104-11. discussion S144-51
   PubMed Web of Science ®Google Scholar
• Besselink MG, van Santvoort HC, Buskens E, Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371:651-9
   PubMed Web of Science ®Google Scholar
• Venugopalan V, Shriner KA, Wong-Beringer A. Regulatory oversight and safety of probiotic use. Emerg Infect Dis 2010.16(11):1661-5.
   Google Scholar
• Cohen SH, Gerding DN, Johnson S, Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-55
   PubMed Web of Science ®Google Scholar
• Gao XW, Mubasher M, Fang CY, Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010;105:1636-41
   PubMed Web of Science ®Google Scholar
• McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 2010;16:2202-22
   PubMed Web of Science ®Google Scholar
• Miller M. The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy. Anaerobe 2009;15:281-4
   PubMed Web of Science ®Google Scholar
• Johnson S, Maziade PJ, McFarland LV, Is primary prevention of Clostridium difficile infection possible with specific probiotics? Int J Infect Dis 2012;16:e786-92
   PubMed Web of Science ®Google Scholar
• Cartman ST. Time to consider Clostridium probiotics? Future Microbiol 2011;6:969-71
   PubMedGoogle Scholar
• Borriello SP, Barclay FE. Protection of hamsters against Clostridium difficile ileocaecitis by prior colonisation with non-pathogenic strains. J Med Microbiol 1985;19:339-50
   PubMed Web of Science ®Google Scholar
• Merrigan MM, Sambol SP, Johnson S, New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration. Int J Antimicrob Agents 2009;33:S46-50
   PubMed Web of Science ®Google Scholar
• Gerding DN, Johnson S. Management of Clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis 2010;51:1306-13
   PubMed Web of Science ®Google Scholar
• Seki H, Shiohara M, Matsumura T, Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatr Int 2003;45:86-90
   PubMed Web of Science ®Google Scholar
• Villano SA, Seiberling M, Tatarowicz W, Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chemother 2012;56:5224-9
   PubMed Web of Science ®Google Scholar
• Gibson GR. Dietary modulation of the human gut microflora using prebiotics. Br J Nut 1998;80:S209-12
   PubMed Web of Science ®Google Scholar
• Roberfroid MB. Prebiotics and synbiotics: concepts and nutritional properties. Br J Nutr 1998;80:S197-202
   PubMed Web of Science ®Google Scholar
• Grizard D, Barthomeuf C. Non-digestible oligosaccharides used as prebiotic agents: mode of production and beneficial effects on animal and human health. Reprod Nutr Dev 1999;39:563-88
   PubMedGoogle Scholar
• Hopkins MJ, Mcfarlane GT. Nondigestible oligosaccharides enhance bacterial colonization resistance against Clostridium difficile in vitro. Appl Environ Microbiol 2003;69:1920-7
   PubMed Web of Science ®Google Scholar
• Euler AR, Mitchell DK, Kline R, Prebiotic effect of fructo-oligosaccharide supplemented term infant formula at two concentrations compared with unsupplemented formula and human milk. J Pediatr Gastroenterol Nutr 2005;40:157-64
   PubMed Web of Science ®Google Scholar
• Rohlke F, Surawicz CM, Stollman N. Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology. J Clin Gastroenterol 2010;44:567-70
   PubMed Web of Science ®Google Scholar
• Brandt LJ, Reddy SS. Fecal microbiota transplantation for recurrent Clostridium difficile infection. J Clin Gastroenterol 2011;45:S159-67
   PubMed Web of Science ®Google Scholar
• Kassam Z, Hundal R, Marshall JK, Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. Arch Intern Med 2012;172:191-3
   PubMed Web of Science ®Google Scholar
• Jorup-Rönström C, Håkanson A, Sandell S, Fecal transplant against relapsing Clostridium difficile-associated diarrhea in 32 patients. Scand J Gastroenterol 2012;47:548-52
   PubMed Web of Science ®Google Scholar
• Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficle diarrhoea in six patients. Lancet 1989;1:1156-60
   PubMed Web of Science ®Google Scholar
• Lawley TD, Clare S, Walker AW, Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 2012;8:e1002995
   PubMed Web of Science ®Google Scholar
• Shen A. Clostridium difficile toxins: mediators of inflammation. J Innate Immun 2012;4:149-58
   Google Scholar
• Gerding DN. Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines. Discov Med 2012;13:75-83
   PubMedGoogle Scholar
• Lowy I, Molrine DC, Leav BA, Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010;362:197-205
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Marbury TC, Foglia G, Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 2012;30:2245-9
   PubMed Web of Science ®Google Scholar
• Baines SD, Freeman J, Wilcox MH. Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection. Antimicrob Agents Chemother 2009;53:2202-4
   PubMed Web of Science ®Google Scholar
• Puri AW, Lupardus PJ, Deu E, Rational design of inhibitors and activity-based probes targeting Clostridium difficile virulence factor TcdB. Chem Biol 2010;17:1201-11
   PubMed Web of Science ®Google Scholar
• Boesecke C, Cooper DA. Toxicity of HIV protease inhibitors: clinical considerations. Curr Opin HIV AIDS 2008;3:653-9
   PubMedGoogle Scholar
• Seal BS. Characterization of bacteriophages virulent for Clostridium perfringens and identification of phage lytic enzymes as alternatives to antibiotics for potential control of the bacterium1. Poult Sci 2013;92:526-33
   PubMed Web of Science ®Google Scholar
• Keen EC. Phage therapy: concept to cure. Front Microbiol 2012;3:238
   PubMed Web of Science ®Google Scholar
• Muniesa M, Hammerl JA, Hertwig S, Shiga toxin-producing Escherichia coli O104:H4: a new challenge for microbiology. Appl Environ Microbiol 2012;78:4065-73
   PubMed Web of Science ®Google Scholar